tiprankstipranks
Advertisement
Advertisement

GNLX Stock Latest News

Buy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
RatingsBuy Rating Reaffirmed on Olvi-Vec Progress and Data Outlook; $31 Price Target Maintained
18d ago
GNLX
Genelux reports Q1 EPS (20c), consensus (19c)
PremiumThe Fly
Genelux reports Q1 EPS (20c), consensus (19c)
19d ago
GNLX
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
PremiumRatings
Buy Rating Backed by Pivotal Olvi-Vec Ovarian Cancer Trial Progress and Multi-Indication Upside Potential
2M ago
GNLX
Genelux price target lowered to $20 from $23 at Benchmark
PremiumThe Fly
Genelux price target lowered to $20 from $23 at Benchmark
2M ago
GNLX
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
PremiumRatings
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside
2M ago
GNLX
Genelux Establishes $100 Million At-The-Market Equity Program
PremiumCompany AnnouncementsGenelux Establishes $100 Million At-The-Market Equity Program
2M ago
8K
GNLX
Genelux Updates Corporate Presentation for Investors and Stakeholders
Premium
Company Announcements
Genelux Updates Corporate Presentation for Investors and Stakeholders
4M ago
8K
GNLX
Genelux Announces Underwritten Public Offering to Raise Capital
Premium
Company Announcements
Genelux Announces Underwritten Public Offering to Raise Capital
5M ago
8K
GNLX
Genelux prices 6.67M shares at $3.00 in underwritten public offering
PremiumThe Fly
Genelux prices 6.67M shares at $3.00 in underwritten public offering
5M ago
GNLX
Genelux announces common stock offering, no amount given
PremiumThe Fly
Genelux announces common stock offering, no amount given
5M ago
GNLX
Genelux data update indicates disease early control, says H.C. Wainwright
PremiumThe Fly
Genelux data update indicates disease early control, says H.C. Wainwright
5M ago
GNLX
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
PremiumRatings
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer
5M ago
GNLX
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials
PremiumCompany AnnouncementsGenelux Reports Encouraging Interim Data for Olvi-Vec Trials
5M ago
8K
GNLX
Genelux reports interim data of systemic administration of Olvi-Vec
Premium
The Fly
Genelux reports interim data of systemic administration of Olvi-Vec
5M ago
GNLX
Genelux Appoints Veteran Oncologist Jason Litten as CMO
Premium
Company Announcements
Genelux Appoints Veteran Oncologist Jason Litten as CMO
5M ago
8K
GNLX
Genelux appoints Jason Litten as CMO
PremiumThe Fly
Genelux appoints Jason Litten as CMO
5M ago
GNLX
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
PremiumRatings
Genelux Corp’s Promising Oncolytic Virus Advancements and Market Potential Drive Buy Rating
7M ago
GNLX
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
PremiumRatings
Promising Clinical Developments in Genelux Corp.’s Olvi-Vec Trials Support Buy Rating
7M ago
GNLX
Genelux reports Q3 EPS (21c), consensus (21c)
PremiumThe Fly
Genelux reports Q3 EPS (21c), consensus (21c)
7M ago
GNLX
Genelux initiated with a Buy at Titan Partners
PremiumThe FlyGenelux initiated with a Buy at Titan Partners
7M ago
GNLX
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
Premium
Company Announcements
Genelux Corp.’s OnPrime Study: A Potential Game-Changer in Ovarian Cancer Treatment
7M ago
GNLX
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
Premium
Company Announcements
Genelux Corp. Advances Phase 2 Study in NSCLC with Promising New Treatment
7M ago
GNLX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >